CD19/CD22 Dual Targeted (Chimeric Antigen Receptor) CAR-T Therapy for Relapsed or RE Fractory (R/R) B-CELL Non-Hodgkin Lymphoma (B-NHL)

被引：0
|
作者：
Zhao, Houli [1 ,2 ,3 ]
Hu, Yongxian [1 ,2 ,3 ]
Nagler, Arnon [4 ]
Chang, Alex Hongsheng [5 ]
Huang, He [1 ,2 ,3 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Hangzhou, Zhejiang, Peoples R China
[4] Chaim Sheba Med Ctr, Tel Hashomer, Israel
[5] Shanghai YaKe Biotechnol Ltd, Shanghai, Shanghai, Peoples R China
来源：
BONE MARROW TRANSPLANTATION | 2020年 / 55卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
O034
引用
收藏
页码：44 / 45
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.
    Liang, Aibin
    Ye, Shiguang
    Li, Ping
    Huang, Jiaqi
    Zhu, Shigui
    Yao, Xin
    Zhou, Lili
    Xu, Yangyang
    Zhu, Judy
    Zheng, Chengxiao
    Chen, Shiyi
    Lan, Liping
    Lv, Xiaoteng
    Wei, Yutian
    Humphries, Michael
    Yao, Yihong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] A CD19/CD20-Directed Bispecific CAR-T Cell Therapy in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma (NHL)
    Larson, Sarah M.
    Chen, Yvonne Y.
    Johnston, Jim
    Roy, Sylvain
    Patel, Pinakin
    Benjamin, Jonathan E.
    BLOOD, 2023, 142
  • [3] Safety and efficacy of a novel anti-CD20/CD19 bispecific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).
    Liang, Aibin
    Zhou, Lili
    Li, Ping
    Yu, Wenjuan
    Yang, Min
    Xu, Yangyang
    Ye, Shiguang
    Zhu, Judy
    Huang, Jiaqi
    Zhang, Yan
    Li, Lanfang
    Zhao, Jing
    Li, Jing
    Zheng, Chengxiao
    Zhu, Kevin
    Lan, Liping
    Zhang, Huilai
    Zhou, Daobin
    Yao, Yihong
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).
    Saifi, Omran
    Breen, William
    Lester, Scott
    Rule, William G.
    Stish, Brad J.
    Rosenthal, Allison Claire
    Munoz, Javier
    Lin, Yi
    Bennani, Nabila Nora
    Paludo, Jonas
    Khurana, Arushi
    Villasboas, Jose Caetano
    Johnston, Patrick B.
    Ansell, Stephen M.
    Iqbal, Madiha
    Moustafa, Muhamad Alhaj
    Murthy, Hemant S.
    Kharfan-Dabaja, Mohamed
    Hoppe, Bradford
    Peterson, Jennifer
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study
    Hu, Yongxian
    Zhang, Yanlei
    Zhao, Houli
    Wang, Yiyun
    Nagler, Arnon
    Chang, Alex Hong
    Huang, He
    BLOOD, 2020, 136
  • [6] Tislelizumab augment the efficacy of CD19/22 dual-targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B-cell non-Hodgkin lymphoma
    Zhang, Ying
    Geng, Hongzhi
    Zeng, Liangyu
    Li, Jiaqi
    Yang, Qin
    Jia, Sixun
    Zong, Xiangping
    Cai, Wenzhi
    Liu, Shuangzhu
    Lu, Yutong
    Yu, Lei
    Li, Caixia
    Wu, Depei
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
  • [7] Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Roddie, Claire
    Lekakis, Lazaros J.
    Marzolini, Maria A. V.
    Ramakrishnan, Aravind
    Zhang, Yiyun
    Hu, Yanqing
    Peddareddigari, Vijay G. R.
    Khokhar, Nushmia
    Chen, Robert
    Basilico, Silvia
    Raymond, Meera
    Vargas, Frederick Arce
    Duffy, Kevin
    Brugger, Wolfram
    O'Reilly, Maeve A.
    Wood, Leigh
    Linch, David C.
    Peggs, Karl S.
    Bachier, Carlos
    Budde, Elizabeth Lihua
    Batlevi, Connie Lee
    Bartlett, Nancy
    Irvine, David
    Tholouli, Eleni
    Osborne, Wendy
    Ardeshna, Kirit M.
    Pule, Martin A.
    BLOOD, 2023, 141 (20) : 2470 - 2482
  • [8] Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma
    Xu, Hao
    Lv, Qiuxia
    Huang, Liang
    Cao, Wenyue
    Wang, Jue
    Meng, Fankai
    Li, Chunrui
    Zheng, Miao
    Chen, Liting
    Mu, Ketao
    Cheng, Jiali
    Zhu, Li
    Zhou, Jianfeng
    Zhang, Yicheng
    Wang, Na
    Cao, Yang
    CYTOTHERAPY, 2023, 25 (02) : 185 - 191
  • [9] CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study
    Wei, Guoqing
    Zhang, Yanlei
    Zhao, Houli
    Wang, Yiyun
    Liu, Yandan
    Liang, Bin
    Wang, Xiujian
    Xu, Huijun
    Cui, Jiazhen
    Wu, Wenjun
    Zhao, Kui
    Nagler, Arnon
    Chang, Alex H.
    Hu, Yongxian
    Huang, He
    CANCER IMMUNOLOGY RESEARCH, 2021, 9 (09) : 1061 - 1070
  • [10] Comprehensive Salvage Radiotherapy for Limited Relapsed B-Cell Non-Hodgkin Lymphoma Following CD19 Chimeric Antigen Receptor T-Cell Therapy
    Saifi, O.
    Breen, W.
    Lester, S. C.
    Rule, W. G.
    Stish, B. J.
    Rosenthal, A.
    Munoz, J.
    Lin, Y.
    Bennani, N.
    Paludo, J.
    Khurana, A.
    Bisneto, J. Villasboas
    Johnston, P.
    Ansell, S. M.
    Iqbal, M.
    Moustafa, M. Alhaj
    Murthy, H. S.
    Kharfan-Dabaja, M.
    Hoppe, B. S.
    Peterson, J. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S56 - S56
12345